These Analysts Slash Their Forecasts On Phreesia Following Q4 Results

Financial Performance - Phreesia reported fourth-quarter earnings of 2 cents, missing the consensus estimate of 7 cents [1] - Sales reached $127.07 million, up 16% year-over-year, beating the consensus of $126.62 million [1] - The average number of healthcare service clients (AHSCs) was 4,658 in the quarter, reflecting a 7% year-over-year increase [1] Fiscal Guidance - The company lowered its fiscal 2027 revenue outlook to $510–$520 million, down from a previous range of $545–$559 million, due to reduced visibility into pharma client spending and weaker-than-expected commitments for the second half of the year [2] Key Milestones - CEO Chaim Indig highlighted several financial milestones, including achieving positive GAAP net income of $2.3 million, crossing $100 million in Adjusted EBITDA, and generating $50 million in free cash flow for fiscal year 2026 [3] - Phreesia shares experienced a significant decline of 28.6%, dropping to $8.14 in pre-market trading following the earnings announcement [3]